{"aliases":[{"type":"Synonym","name":"trastuzumab-strf"},{"type":"USBrandName","name":"Hercessi"},{"type":"Synonym","name":"trastuzumab biosimilar QL1701"},{"type":"USBrandName","name":"Kanjinti"},{"type":"Synonym","name":"trastuzumab-anns"},{"type":"USBrandName","name":"Ontruzant"},{"type":"Synonym","name":"trastuzumab-dttb"},{"type":"USBrandName","name":"Trazimera"},{"type":"Synonym","name":"trastuzumab-qyyp"},{"type":"CodeName","name":"ABP 980"},{"type":"Synonym","name":"anti-c-erB-2"},{"type":"Synonym","name":"anti-c-erbB2 monoclonal antibody"},{"type":"Synonym","name":"anti-ERB-2"},{"type":"Synonym","name":"anti-erbB-2"},{"type":"Synonym","name":"anti-erbB2 monoclonal antibody"},{"type":"Synonym","name":"anti-HER2/c-erbB2 monoclonal antibody"},{"type":"Synonym","name":"anti-p185-HER2"},{"type":"LexicalVariant","name":"HER2 monoclonal antibody"},{"type":"USBrandName","name":"Herceptin"},{"type":"Synonym","name":"Herceptin biosimilar PF-05280014"},{"type":"Synonym","name":"trastuzumab biosimilar PF-05280014"},{"type":"Abbreviation","name":"MoAB HER2"},{"type":"Synonym","name":"MoAB HER2"},{"type":"Synonym","name":"monoclonal antibody HER2"},{"type":"Synonym","name":"monoclonal antibody c-erb-2"},{"type":"USBrandName","name":"Ogivri"},{"type":"CodeName","name":"PF-05280014"},{"type":"Abbreviation","name":"rhuMAb HER2"},{"type":"CodeName","name":"RO0452317"},{"type":"Synonym","name":"trastuzumab biosimilar PF-05280014"},{"type":"Synonym","name":"trastuzumab biosimilar SIBP-01"},{"type":"Synonym","name":"trastuzumab biosimilar ABP 980"},{"type":"Synonym","name":"trastuzumab biosimilar SB3"},{"type":"Synonym","name":"trastuzumab biosimilar HLX02"},{"type":"Synonym","name":"trastuzumab biosimilar ALT02"},{"type":"Synonym","name":"trastuzumab biosimilar EG12014"},{"type":"USBrandName","name":"Herzuma"},{"type":"NSCNumber","name":"688097"},{"type":"CASRegistryName","name":"180288-69-1"},{"type":"CodeName","name":"ALT02"},{"type":"Synonym","name":"c-erb-2 monoclonal antibody"},{"type":"Synonym","name":"Herceptin trastuzumab biosimilar PF-05280014"},{"type":"ChemicalStructureName","name":"immunoglobulin G 1 (human-mouse monoclonal RhuMab HER2gamma1-chain antihuman p185(Sup c-erbB2) receptor), disulfide with human-mouse monoclonal RhuMab HER2 light chain, dimer"},{"type":"CodeName","name":"QL 1701"},{"type":"CodeName","name":"QL-1701"},{"type":"CodeName","name":"QL1701"},{"type":"CodeName","name":"SB3"},{"type":"Synonym","name":"trastuzumab-dkst"},{"type":"Synonym","name":"trastuzumab-pkrb"},{"type":"CodeName","name":"CT-P06"},{"type":"CodeName","name":"CT-P6"},{"type":"Synonym","name":"trastuzumab biosimilar CT-P6"},{"type":"ForeignBrandName","name":"Biceltis"},{"type":"ForeignBrandName","name":"CANMab"},{"type":"ForeignBrandName","name":"Herclon"},{"type":"ForeignBrandName","name":"Hertraz"}],"definition":{"html":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.","text":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab","text":"Trastuzumab"},"nciConceptId":"C1647","nciConceptName":"Trastuzumab","termId":42265,"name":"trastuzumab","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"trastuzumab"}